CN102209711B - 用于治疗丙型肝炎的化合物 - Google Patents
用于治疗丙型肝炎的化合物 Download PDFInfo
- Publication number
- CN102209711B CN102209711B CN200980144810.1A CN200980144810A CN102209711B CN 102209711 B CN102209711 B CN 102209711B CN 200980144810 A CN200980144810 A CN 200980144810A CN 102209711 B CN102209711 B CN 102209711B
- Authority
- CN
- China
- Prior art keywords
- solvent
- fluorophenyl
- gradient
- pyridine
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ZBVNXWBKKNJXSU-UHFFFAOYSA-N CC(C)(c1ccccc1)NC(c1cc(-c2cc3c(C(O)=O)c(-c(cc4)ccc4F)n[n]3cc2N(CCO)S(C)(=O)=O)ccc1)=O Chemical compound CC(C)(c1ccccc1)NC(c1cc(-c2cc3c(C(O)=O)c(-c(cc4)ccc4F)n[n]3cc2N(CCO)S(C)(=O)=O)ccc1)=O ZBVNXWBKKNJXSU-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)(c1ccccc1)NC(c1cc(-c2ccncc2N(CC*)S(C)(=O)=O)ccc1)=O Chemical compound CC(C)(c1ccccc1)NC(c1cc(-c2ccncc2N(CC*)S(C)(=O)=O)ccc1)=O 0.000 description 1
- LOWZRASZEBOGTC-UHFFFAOYSA-N CC(C)(c1ccccc1)NC(c1cccc(-c2cc3c(C(NC)=O)c(-c(cc4)ccc4F)n[n]3cc2NS(C)(=N)=O)c1)=O Chemical compound CC(C)(c1ccccc1)NC(c1cccc(-c2cc3c(C(NC)=O)c(-c(cc4)ccc4F)n[n]3cc2NS(C)(=N)=O)c1)=O LOWZRASZEBOGTC-UHFFFAOYSA-N 0.000 description 1
- UZNUPXTUWKSZCI-UHFFFAOYSA-N CCN(c(c(-c1ccccc1)cc1c2C(NC)=O)c[n]1nc2-c(cc1)ccc1F)S(C)(=O)=O Chemical compound CCN(c(c(-c1ccccc1)cc1c2C(NC)=O)c[n]1nc2-c(cc1)ccc1F)S(C)(=O)=O UZNUPXTUWKSZCI-UHFFFAOYSA-N 0.000 description 1
- MKNPLYKEDQXBSW-UHFFFAOYSA-N CCOC(c1c(-c(cc2)ccc2F)nc(cc2)[n]1cc2Br)=O Chemical compound CCOC(c1c(-c(cc2)ccc2F)nc(cc2)[n]1cc2Br)=O MKNPLYKEDQXBSW-UHFFFAOYSA-N 0.000 description 1
- GIGQRUJVNJBXDZ-UHFFFAOYSA-N CNC(c1c(ccc(-c(cccc2)c2OC)c2)[n]2nc1-c1ccccc1)=O Chemical compound CNC(c1c(ccc(-c(cccc2)c2OC)c2)[n]2nc1-c1ccccc1)=O GIGQRUJVNJBXDZ-UHFFFAOYSA-N 0.000 description 1
- ZVMKAOAHQZDGIY-UHFFFAOYSA-N Cc(c(-c1cc2c(C(NC)=O)c(-c(cc3)ccc3F)n[n]2c(C)c1)c1)ccc1C(NC1(CC1)c1ccccc1)=O Chemical compound Cc(c(-c1cc2c(C(NC)=O)c(-c(cc3)ccc3F)n[n]2c(C)c1)c1)ccc1C(NC1(CC1)c1ccccc1)=O ZVMKAOAHQZDGIY-UHFFFAOYSA-N 0.000 description 1
- WXKUXIOUHYOLCU-UHFFFAOYSA-N Cc(cc(c(C(NC1(CC1)C1CC1)=O)c1)OC)c1-c(cc[n](c1c2C(NC)=O)nc2-c(cc2)ccc2F)c1F Chemical compound Cc(cc(c(C(NC1(CC1)C1CC1)=O)c1)OC)c1-c(cc[n](c1c2C(NC)=O)nc2-c(cc2)ccc2F)c1F WXKUXIOUHYOLCU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9600408P | 2008-09-11 | 2008-09-11 | |
| US61/096,004 | 2008-09-11 | ||
| PCT/US2009/055648 WO2010030538A2 (en) | 2008-09-11 | 2009-09-02 | Compounds for the treatment of hepatitis c |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410060239.8A Division CN103864783A (zh) | 2008-09-11 | 2009-09-02 | 用于治疗丙型肝炎的化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102209711A CN102209711A (zh) | 2011-10-05 |
| CN102209711B true CN102209711B (zh) | 2014-06-18 |
Family
ID=41203516
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410060239.8A Pending CN103864783A (zh) | 2008-09-11 | 2009-09-02 | 用于治疗丙型肝炎的化合物 |
| CN200980144810.1A Expired - Fee Related CN102209711B (zh) | 2008-09-11 | 2009-09-02 | 用于治疗丙型肝炎的化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410060239.8A Pending CN103864783A (zh) | 2008-09-11 | 2009-09-02 | 用于治疗丙型肝炎的化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8198449B2 (OSRAM) |
| EP (1) | EP2331502B1 (OSRAM) |
| JP (1) | JP2012502099A (OSRAM) |
| KR (1) | KR20110056537A (OSRAM) |
| CN (2) | CN103864783A (OSRAM) |
| AR (1) | AR073586A1 (OSRAM) |
| AU (1) | AU2009291993A1 (OSRAM) |
| MX (1) | MX2011002471A (OSRAM) |
| TW (1) | TW201014855A (OSRAM) |
| WO (1) | WO2010030538A2 (OSRAM) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ599597A (en) | 2009-10-30 | 2013-05-31 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| IN2012DN04917A (OSRAM) | 2009-11-05 | 2015-09-25 | Univ Notre Dame Du Lac | |
| FR2953520B1 (fr) * | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| US8324212B2 (en) * | 2010-02-25 | 2012-12-04 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| EP2545050B1 (en) * | 2010-03-10 | 2014-08-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| US8354410B2 (en) | 2010-03-11 | 2013-01-15 | Bristol-Meyers Squibb Company | Compounds for the treatment of hepatitis C |
| AR082453A1 (es) * | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
| US8445497B2 (en) | 2010-06-30 | 2013-05-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| NZ610331A (en) * | 2010-10-20 | 2015-01-30 | Biota Scient Management | Viral polymerase inhibitors |
| CN103269586B (zh) | 2010-10-26 | 2015-07-15 | 普雷西迪奥制药公司 | 丙型肝炎病毒抑制剂 |
| EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| WO2013000924A1 (en) | 2011-06-27 | 2013-01-03 | Janssen Pharmaceutica Nv | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9303020B2 (en) | 2012-02-08 | 2016-04-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| IN2014MN01547A (OSRAM) | 2012-02-10 | 2015-05-08 | Lupin Ltd | |
| EP2831066B1 (en) | 2012-03-27 | 2016-10-05 | Bristol-Myers Squibb Company | Benzofuran derivatives for the treatment of hepatitis c |
| US9365554B2 (en) | 2012-04-11 | 2016-06-14 | Aviragen Therapeutics, Inc. | Viral polymerase inhibitors |
| WO2013163466A1 (en) * | 2012-04-25 | 2013-10-31 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
| CN102690264B (zh) * | 2012-06-20 | 2014-07-02 | 泰山医学院 | 2-苯基-3-取代咪唑并[1,2-a]吡啶类衍生物及其制备方法 |
| WO2014001314A1 (en) | 2012-06-26 | 2014-01-03 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| AU2013289284B2 (en) | 2012-07-09 | 2017-03-30 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
| US9126998B2 (en) | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US8796305B2 (en) | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
| US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| ES2655030T3 (es) | 2012-11-19 | 2018-02-16 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| US8962651B2 (en) * | 2013-03-13 | 2015-02-24 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| EP3004094B1 (de) | 2013-06-04 | 2017-03-01 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung |
| TW201609651A (zh) * | 2013-11-12 | 2016-03-16 | 陶氏農業科學公司 | 用於氟化化合物之過程（一） |
| US9688699B2 (en) | 2014-02-19 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
| EP3119777A1 (de) | 2014-03-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
| ES2688554T3 (es) * | 2014-03-21 | 2018-11-05 | Bristol-Myers Squibb Company | Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis C |
| EP3119769A1 (en) * | 2014-03-21 | 2017-01-25 | Bristol-Myers Squibb Pharma Company | Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis c |
| JP2017514898A (ja) | 2014-05-02 | 2017-06-08 | バイエル・ファルマ・アクティエンゲゼルシャフト | 心血管疾患の治療のためのｎ−（２−アミノ−５−フルオロ−２−メチルペンチル）−８−［（２，６−ジフルオロベンジル）オキシ］−２−メチルイミダゾ［１，２−ａ］ピリジン−３−カルボキサミドの、並びにジ−及びトリフルオロ誘導体のエナンチオマー |
| US9957278B2 (en) * | 2014-08-05 | 2018-05-01 | Bristol-Myers Squibb Company | Furopyridine compounds for the treatment of hepatitis C |
| BR112017006117A2 (pt) * | 2014-09-26 | 2017-12-19 | Changzhou Yinsheng Pharmaceutical Co Ltd | análogo de benzofurano como inibidor de ns4b |
| CN107001361A (zh) | 2014-12-02 | 2017-08-01 | 拜耳医药股份有限公司 | 杂芳基取代的咪唑并[1，2‑a]吡啶及其用途 |
| IL257743B (en) | 2015-09-17 | 2022-08-01 | Marvin J Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
| WO2018184976A1 (de) | 2017-04-05 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
| RU2019123849A (ru) * | 2019-07-29 | 2021-02-01 | Дзе Брихэм Энд Уимен`З Хоспитал, Инк. | Ингибиторы фактора ингибирования миграции макрофагов |
| WO2024102699A1 (en) * | 2022-11-07 | 2024-05-16 | ELANCO US, Inc. | Guanylate cyclase (gc) stimulator formulations and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002016359A1 (en) * | 2000-08-22 | 2002-02-28 | Glaxo Group Limited | Fused pyrazole derivatives being protein kinase inhibitors |
| WO2002078701A1 (en) * | 2001-03-30 | 2002-10-10 | Smithkline Beecham Corporation | Use of pyrazolopyridines as therapeutic compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3502707A (en) * | 1967-09-11 | 1970-03-24 | Mcneilab Inc | Beta-(cyclohexyl and substituted phenyl)-alpha-(4,5-dimethoxy-2-nitro- or aminophenyl) acrylonitriles |
| JPS57123181A (en) | 1981-01-23 | 1982-07-31 | Mitsubishi Paper Mills Ltd | Preparation of pyrazolo (1,5-a) pyridine derivative |
| DE59303357D1 (de) | 1992-10-29 | 1996-09-05 | Hoechst Ag | Verfahren zur Herstellung von aromatischen Brommethyl-Verbindungen |
| ATE239013T1 (de) * | 1997-12-19 | 2003-05-15 | Lilly Co Eli | Hypoglykamische imidazoline derivate |
| AUPQ969800A0 (en) * | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| CA2484631A1 (en) | 2002-05-13 | 2003-11-27 | Merck & Co., Inc. | Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles |
| AU2003290584B2 (en) * | 2002-11-01 | 2009-07-16 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases |
| TW200528459A (en) * | 2004-01-06 | 2005-09-01 | Achillion Pharmaceuticals Inc | Azabenzofuran substituted thioureas; inhibitors of viral replication |
| US7868037B2 (en) * | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US20090281120A1 (en) | 2005-12-12 | 2009-11-12 | Ono Pharmaceutical Co., Ltd | Bicyclic heterocyclic compound |
| CA2672960A1 (en) * | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
| MX2009008439A (es) * | 2007-02-12 | 2009-08-13 | Intermune Inc | Nuevos inhibidores de la replicacion del virus de hepatitis c. |
| JP2008247878A (ja) | 2007-03-30 | 2008-10-16 | Maruishi Pharmaceutical Co Ltd | イミダゾピリジンおよびイミダゾピリミジン化合物ならびにそれを含有する麻酔または鎮静薬組成物 |
| GB0707000D0 (en) | 2007-04-12 | 2007-05-30 | Istituto Di Ricerche D Biolog | Antiviral agents |
| KR20100117073A (ko) | 2008-02-14 | 2010-11-02 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 항바이러스 화합물 |
| WO2009137493A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 2-substituted benzofuran compounds to treat infection with hepatitis c virus |
| WO2009137500A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
| US8048887B2 (en) * | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7994171B2 (en) * | 2008-09-11 | 2011-08-09 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
-
2009
- 2009-08-28 US US12/549,983 patent/US8198449B2/en active Active
- 2009-09-02 KR KR1020117008086A patent/KR20110056537A/ko not_active Withdrawn
- 2009-09-02 JP JP2011526911A patent/JP2012502099A/ja active Pending
- 2009-09-02 AU AU2009291993A patent/AU2009291993A1/en not_active Abandoned
- 2009-09-02 CN CN201410060239.8A patent/CN103864783A/zh active Pending
- 2009-09-02 WO PCT/US2009/055648 patent/WO2010030538A2/en not_active Ceased
- 2009-09-02 MX MX2011002471A patent/MX2011002471A/es active IP Right Grant
- 2009-09-02 EP EP09792143.1A patent/EP2331502B1/en not_active Not-in-force
- 2009-09-02 CN CN200980144810.1A patent/CN102209711B/zh not_active Expired - Fee Related
- 2009-09-11 TW TW098130826A patent/TW201014855A/zh unknown
- 2009-09-11 AR ARP090103513A patent/AR073586A1/es not_active Application Discontinuation
-
2012
- 2012-05-14 US US13/470,727 patent/US8536338B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002016359A1 (en) * | 2000-08-22 | 2002-02-28 | Glaxo Group Limited | Fused pyrazole derivatives being protein kinase inhibitors |
| WO2002078701A1 (en) * | 2001-03-30 | 2002-10-10 | Smithkline Beecham Corporation | Use of pyrazolopyridines as therapeutic compounds |
Non-Patent Citations (2)
| Title |
|---|
| Acid-Catalyzed Reactions of 3-(Hydroxymethyl)- and 3-(1-hydroxyethyl)pyrazolo[1,5-a]pyridines;Yasuyoshi Miki，et al.;《Journal of Heterocyclic Chemistry》;19891231;第26卷(第6期);1739-1745 * |
| Preparation of New Nitrogen-Bridged Heterocycles. XIV. Further Investigation of the Desulfurization and the Rearrangement of Pyrido[1,2-d]-1,3,4-thiadiazine Intermediates;AKIKAZU KAKEHI，et al.;《Chemical & Pharmaceutical Bulletin》;19871231;第35卷(第1期);156-169 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201014855A (en) | 2010-04-16 |
| JP2012502099A (ja) | 2012-01-26 |
| CN103864783A (zh) | 2014-06-18 |
| EP2331502A2 (en) | 2011-06-15 |
| AU2009291993A1 (en) | 2010-03-18 |
| AR073586A1 (es) | 2010-11-17 |
| WO2010030538A3 (en) | 2010-05-06 |
| WO2010030538A2 (en) | 2010-03-18 |
| KR20110056537A (ko) | 2011-05-30 |
| US8536338B2 (en) | 2013-09-17 |
| CN102209711A (zh) | 2011-10-05 |
| US20100063068A1 (en) | 2010-03-11 |
| US20120232099A1 (en) | 2012-09-13 |
| US8198449B2 (en) | 2012-06-12 |
| EP2331502B1 (en) | 2016-03-02 |
| MX2011002471A (es) | 2011-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102209711B (zh) | 用于治疗丙型肝炎的化合物 | |
| CN102906089A (zh) | 用于治疗丙型肝炎的化合物 | |
| US8293909B2 (en) | Compounds for the treatment of hepatitis C | |
| CN102325752B (zh) | 咔唑和咔啉激酶抑制剂 | |
| CN102665718B (zh) | 可用作pdk1抑制剂的杂环化合物 | |
| CN109195965B (zh) | Wdr5蛋白质-蛋白质结合的抑制剂 | |
| CN110582493A (zh) | 作为免疫调节剂的苯并噁唑衍生物 | |
| CN106661056B (zh) | 作为酪蛋白激酶1δ/ε抑制剂的咪唑并哒嗪衍生物 | |
| CN101965347B (zh) | 作为激酶抑制剂的吡唑并吡啶 | |
| CN114901279A (zh) | 用于治疗自身炎性疾病和癌症转移的cGAS的抑制剂 | |
| WO2007147874A1 (en) | Pyridine and pyrazine derivatives as mnk kinase inhibitors | |
| CN101657430A (zh) | 有机化合物及其用途 | |
| CN106794161A (zh) | TrkA激酶抑制剂、组合物及其方法 | |
| JP2013521237A (ja) | Ｃ型肝炎ウィルスｎｓ５ｂポリメラーゼの阻害薬 | |
| CN105732614B (zh) | 磺酰胺基芳基炔类化合物及其用途 | |
| CN106456582A (zh) | TrkA 激酶抑制剂、组合物及其方法 | |
| CN107922407B (zh) | 呼吸道合胞病毒抑制剂 | |
| CN102892767A (zh) | 治疗丙型肝炎的化合物 | |
| CN102414212A (zh) | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| CN118201924A (zh) | 杂环化合物及其用途 | |
| JP2016516787A (ja) | 置換縮合ピリミジン化合物 | |
| CN103298791B (zh) | 病毒聚合酶抑制剂 | |
| JP2018509401A (ja) | Ｃ型肝炎の治療のための新規化合物 | |
| CN112689636B (zh) | 新型杂原子芳香族酰胺衍生物以及含有其的药剂 | |
| WO2022007966A1 (zh) | Pb2抑制剂及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140618 Termination date: 20200902 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |